We have a robust and sustainable pipeline with 3 clinical stage assets (EMB-01, EMB-06 and EMB-07) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint regulators, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
Program
Target
Indication
Line(s) of treatment
Mono/
Combo
Combo
PCC
IND-
Enabling
Enabling
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
Key Regulatory Authorities
Current Status/Upcoming Milestone
Rights
Partners
Oncology
Clinical
EMB-01 EGFR/cMET
Advanced/metastatic GI Cancers(CRC, HCC, gastric, biliary tract cancer)
≥3L
Mono
FDA,NMPA
Phase Ib/II trial completion in April 2026
Global
/
mCRC
≥3L
Mono
NMPA
First patient enrolled in Phase II trial in December 2025/Expected Phase II trial primary completion in December 2027
Global
/
mCRC
2L,3L
+Chemo
NMPA
IND approval from the NMPA in January 2024/Expected Phase Ib initiation in Q3 2026
Global
/
EMB-07 ROR1/CD3
Solid tumors and R /R lymphoma
≥2L/≥3L
Mono
NMPA
Dos-escalation ongoing/Expected Phase I trial completion in Q4 2026
Global
/
DLBCL
1L,2L
Combo
NMPA
First patient enrolled in May 2026/Expected Phase I trial completion in Q2 2028
Global
/
EMB-15
ALPP(G)/CD3
Solid tumors
≥2L
Mono
NMPA
First patient enrolled in June 2026/ Expected Phase I trial completion in Q2 2029
Global
/
Pre-Clinical
EM1033（ProTCE）
CD228/CD3
Solid tumors
/
TBD
/
IND-enabling ongoing/ Expected IND submission in Q3 2027
Global
/
EM1034
LY6G6D/ CD3
Solid tumors
/
TBD
/
IND-enabling ongoing/ Expected IND submission in Q4 2027
Global
/
Immunology
Clinical
EMB-06 BCMA/CD3
SLE、gMG, TED
Relapsed/ Refractory
Mono
NMPA
Ongoing Phase I trials in SLE , gMG and TED sponsored by Candid
China
Candid
Pre-Clinical
EM1039
Undisclosed trispecific TCE
Autoimmune diseases (B cell related)
/
TBD
/
IND-enabling ongoing/ Expected IND submission in Q2 2027
Global
/
EM1042
Undisclosed TCE
Autoimmune diseases (Inflammatory cell related)
/
TBD
/
IND-enabling ongoing/ Expected IND submission in Q1 2027
Global
/
TCE Programs
Non-TCE Programs
Core Product
Key Product
TCE Programs
Non-TCE Programs
Core Product
Key Product
